Text Size

Efficacy and safety of 0.1% ciclosporin A cationic emulsion in dry eye disease: A pooled analysis of two double-masked, randomised, vehicle-controlled phase III clinical studies

Leonardi A., Messmer E.M., Labetoulle M., Amrane M., Garrigue J.-S., Ismail D., Sainz-De-La-Maza M., Figueiredo F.C., Baudouin C.

  • 2019
  • British Journal of Ophthalmology
View publication
  • Therapeutic Area

    Front of the eye (FOTE)

  • Technology


  • Categories

    Clinical development

  • Affiliations

    Department of Neuroscience, Ophthalmology Unit, University of Padua, Giustiniani 2, Padua, 35128, Italy; Department of Ophthalmology, Ludwig-Maximilian University of Munich, Munich, Germany; Department of Ophthalmology, Bicêtre Hospital, APHP, Paris-Sud University, Le Kremlin Bicêtre, France; Santen SAS, Evry, France; Institute Clinic of Ophthalmology, Hospital Clinic of Barcelona, University of Barcelona, Barcelona, Spain; Department of Ophthalmology, Royal Victoria Infirmary, Newcastle University, Newcastle Upon Tyne, United Kingdom; Quinze-Vingts National Ophthalmology Hospital, Paris, France; Vision Institute, INSERM UMRS968, CNRS UMR7210, UPMC University, Paris, France; University of Versailles Saint-Quentin en Yvelines, Versailles, France

Related Publications

Burden of Vernal Keratoconjunctivitis in the United States: A Retrospective Claims Database Analysis

Koo E.B.; Yu T.M.; Layton A.J.; Babineaux S.; Fung S.

Review of clinical outcomes of a cationic emulsion tear substitute in patients with dry eye disease

Labetoulle M, Garhöfer G, Ismail D, Garrigue JS, Amrane M, Guillon M, Aragona P, Baudouin C.

Epinastine Cream: A Novel Once-Daily Therapeutic Agent for Allergic Conjunctivitis

Ogura N., Fujisawa K., Kato M.

Can't find what you're looking for?

Contact us

Document number: NP-No product-EMEA-0110
Date of preparation: February 2022